PRINCETON, N.J., Feb. 4, 2011 /PRNewswire/ -- Novo Nordisk announced today the availability of Coags Uncomplicated the first mobile application (app) to assist in the diagnosis of bleeding disorders created in partnership with Craig Kessler, MD, Professor of Medicine and Pathology and Director of the Coagulation Laboratory, Georgetown University Hospital, Lombardi Comprehensive Cancer Center. Coags Uncomplicated features a Lab Value Analyzer that enables physicians to input test results and receive a list of potential diagnoses to consider including a description of each bleeding disorder and typical lab values. The app also provides step-by-step suggestions for appropriate lab tests to narrow possible diagnoses.
With the potential to help clinicians quickly and more accurately diagnose bleeding disorders, the app provides for the first time, in one place, information about bleeding disorders and their effects on coagulation laboratory tests.
"While physicians are increasingly using hand-held devices to access medical information, no such tool has existed to help with the diagnosis of bleeding disorders, especially when getting to the correct diagnosis quickly may be critical," said Eddie Williams, Vice President, Biopharmaceuticals. "Novo Nordisk was pleased to collaborate with Dr. Kessler on this innovative approach to addressing an unmet need, further demonstrating our commitment to the bleeding disorder community."
The basis for the app came from U.S. market research results, which identified a gap in many specialists' recognition of abnormal blood clotting activity in a bleeding patient; often resulting in a focus on the location of the bleed rather than the cause. These findings were presented at the 2010 American Society of Hematology (ASH) Annual Meeting.
The Coags Uncomplicated app is available for free download at www.coagsuncomplicated.com. For individuals who do not have an iPhone, the app tools and additional information can also be accessed online.
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 29,650 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.
iPhone and iTunes are registered trademarks of Apple Inc.
SOURCE Novo Nordisk